101 results
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability … internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
writing prospectus provided in connection with this offering. Neither we nor the underwriters take any responsibility for, and provide no assurance … , and there can be no assurance that the IRS will agree with such statements and conclusions or will not take a contrary position regarding the tax
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. You should not assume … to the statements made and the conclusions reached in the
S-18
following summary, and there can be no assurance that the IRS will agree
8-K
EX-99.1
joeus 1togqqyf
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
8-K
EX-99.1
l46 nmc4w
11 Mar 24
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
7:02am
8-K
EX-99.1
24k53gp
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.1
ei7fe
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.2
pa3fbcvd57zf1no7y7
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
ag91hgy q4quhf
11 Dec 23
Other Events
12:03pm
8-K
EX-99.1
xfktwqdr60gvwqs xc
13 Nov 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
11apyu
1 Nov 23
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
4:02pm